MX422201B - Composiciones comprimidas de macitentan, metodos y usos de las mismas - Google Patents

Composiciones comprimidas de macitentan, metodos y usos de las mismas

Info

Publication number
MX422201B
MX422201B MX2022000267A MX2022000267A MX422201B MX 422201 B MX422201 B MX 422201B MX 2022000267 A MX2022000267 A MX 2022000267A MX 2022000267 A MX2022000267 A MX 2022000267A MX 422201 B MX422201 B MX 422201B
Authority
MX
Mexico
Prior art keywords
macitentan
compositions
compressed
relates
methods
Prior art date
Application number
MX2022000267A
Other languages
English (en)
Other versions
MX2022000267A (es
Inventor
Serra João Pedro Silva
Pereira Ricardo José Camilo Ferreira
Original Assignee
Tecnimede Sociedade Tecnico Medicinal Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71899791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX422201(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tecnimede Sociedade Tecnico Medicinal Sa filed Critical Tecnimede Sociedade Tecnico Medicinal Sa
Publication of MX2022000267A publication Critical patent/MX2022000267A/es
Publication of MX422201B publication Critical patent/MX422201B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación también se refiere a composiciones comprimidas que comprenden una cantidad terapéuticamente eficaz de macitentán, un diluyente de alcohol de azúcar y un tensioactivo; también se refiere al procedimiento de obtención de dichas composiciones comprimidas, a composiciones farmacéuticas orales que las comprenden, y a su uso en el tratamiento de hipertensión arterial pulmonar; la presente divulgación también se refiere a composiciones farmacéuticas orales sólidas que comprenden una cantidad terapéuticamente eficaz de macitentán que simultáneamente presentan propiedades de estabilidad mejoradas y perfiles de disolución adecuados, lo que presenta una necesidad insatisfecha en el campo de la formulación farmacéutica de macitentán.
MX2022000267A 2019-07-05 2020-07-03 Composiciones comprimidas de macitentan, metodos y usos de las mismas MX422201B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT11563219 2019-07-05
EP19185065 2019-07-08
PCT/IB2020/056304 WO2021005478A1 (en) 2019-07-05 2020-07-03 Compressed macitentan compositions, methods and uses thereof

Publications (2)

Publication Number Publication Date
MX2022000267A MX2022000267A (es) 2022-02-03
MX422201B true MX422201B (es) 2025-04-10

Family

ID=71899791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000267A MX422201B (es) 2019-07-05 2020-07-03 Composiciones comprimidas de macitentan, metodos y usos de las mismas

Country Status (14)

Country Link
US (1) US20220249381A1 (es)
EP (2) EP3993777B1 (es)
CN (1) CN114096239B (es)
AU (1) AU2020309223B2 (es)
BR (1) BR112022000117A2 (es)
CA (1) CA3144613A1 (es)
CL (1) CL2022000008A1 (es)
CO (1) CO2021017646A2 (es)
DK (1) DK3993777T3 (es)
FI (1) FI3993777T3 (es)
HU (1) HUE068040T2 (es)
MX (1) MX422201B (es)
PE (1) PE20220593A1 (es)
WO (1) WO2021005478A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317119A (zh) * 2021-06-11 2023-05-01 瑞士商艾克泰聯製藥有限公司 用於口服投予之分散錠
EP4154873A1 (en) * 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan
EP4456983A4 (en) * 2021-12-30 2025-09-17 Humanis Saglik Anonim Sirketi PHARMACEUTICAL COMPOSITIONS COMPRISING MACITENTAN AS ACTIVE INGREDIENT AND OTHER RELEVANT EXCIPIENTS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693372A1 (en) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Novel Sulfamides and their use as endothelin receptor antagonists
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
US9101565B2 (en) * 2008-11-17 2015-08-11 Takeda Nycomed As Dissolution stability of calcium carbonate tablets
DE14721256T1 (de) * 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
CN104411691B (zh) * 2013-06-14 2016-05-25 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
IN201641002749A (es) 2016-01-25 2017-09-15 Hetero Research Foundation
CN107913256A (zh) * 2016-10-08 2018-04-17 郑州泰丰制药有限公司 一种治疗肺动脉高压的马西替坦口腔崩解片及其制备方法
WO2018153925A1 (en) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
CN109260163A (zh) * 2018-10-07 2019-01-25 威海云睿信息科技有限公司 一种马西替坦片剂组合物

Also Published As

Publication number Publication date
EP4417254B1 (en) 2026-08-05
PE20220593A1 (es) 2022-04-22
FI3993777T3 (fi) 2024-09-10
CL2022000008A1 (es) 2022-10-07
HUE068040T2 (hu) 2024-12-28
WO2021005478A1 (en) 2021-01-14
EP3993777A1 (en) 2022-05-11
US20220249381A1 (en) 2022-08-11
BR112022000117A2 (pt) 2022-02-15
EP3993777B1 (en) 2024-06-12
DK3993777T3 (da) 2024-09-16
CO2021017646A2 (es) 2022-01-17
CA3144613A1 (en) 2021-01-14
AU2020309223A1 (en) 2022-03-03
CN114096239A (zh) 2022-02-25
CN114096239B (zh) 2024-04-12
AU2020309223B2 (en) 2025-05-29
MX2022000267A (es) 2022-02-03
EP4417254A2 (en) 2024-08-21
EP4417254A3 (en) 2025-03-05